Outlook Therapeutics, Inc.OTLKNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P21
Within normal range
vs 5Y Ago
-0.7x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -39.22% |
| Q3 2025 | -16.20% |
| Q2 2025 | 61.89% |
| Q1 2025 | -54.38% |
| Q4 2024 | -22.86% |
| Q3 2024 | 11.79% |
| Q2 2024 | -17.08% |
| Q1 2024 | 198.28% |
| Q4 2023 | -8.39% |
| Q3 2023 | -55.47% |
| Q2 2023 | 1937.26% |
| Q1 2023 | -94.47% |
| Q4 2022 | 9.70% |
| Q3 2022 | -20.08% |
| Q2 2022 | -7.95% |
| Q1 2022 | 23.78% |
| Q4 2021 | -0.63% |
| Q3 2021 | 16.27% |
| Q2 2021 | 0.19% |
| Q1 2021 | -28.62% |
| Q4 2020 | 56.75% |
| Q3 2020 | -10.19% |
| Q2 2020 | 93.66% |
| Q1 2020 | -25.04% |
| Q4 2019 | 30.14% |
| Q3 2019 | 3.45% |
| Q2 2019 | -26.84% |
| Q1 2019 | -2.24% |
| Q4 2018 | -15.07% |
| Q3 2018 | 23.34% |
| Q2 2018 | 12.41% |
| Q1 2018 | 1181.31% |
| Q4 2017 | -80.46% |
| Q3 2017 | -50.48% |
| Q2 2017 | 1.00% |
| Q1 2017 | -68.88% |
| Q4 2016 | 214.06% |
| Q3 2016 | -64.95% |
| Q2 2016 | 190.43% |
| Q1 2016 | -67.50% |